Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus metronomic paclitaxel in adrenocortical carcinoma after prior chemotherapy
2008-000759-91Phase 2Terminated
- Sponsor
- San Luigi Gonzaga Hospital
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and paclitaxel in adrenal cancer (ACC) and Endocrinopathy, sponsored by San Luigi Gonzaga Hospital. Primary endpoints: Progression-free survival and Clinical benefit at 4 months. Started Jul 2008; status: terminated.
02
Drugs
sorafenibpaclitaxel
03
Conditions
adrenal cancer (ACC)Endocrinopathy
Beyond the preview
Go deeper on 2008-000759-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000759-91.